Immunophenotypic Characterization of Citrate-Containing A Concentrates in Maintenance Hemodialysis: A Pre-Post Study

Table 2

Changes in clinical parameters after switching to citrate-acidified A concentrates.

Parameter	Treatment (mean ± SD)		Linear mixed model
			Main effect: treatment
	Acetate	Citrate	Estimate (β)	value
C-reactive protein (g/L)	11.8 ± 24.4	9.9 ± 13.4	−2.8	0.18
IL-6 (pg/ml)	10.5 ± 11.7	17.5 ± 18.8	7.0	0.005
Neutrophils (10^3/μl)	4.6 ± 2.4	4.6 ± 1.5	−0.02	0.95
Lymphocytes (10^3/μl)	1.5 ± 0.6	1.5 ± 0.5	−0.03	0.51
Neutrophils/lymphocytes	3.3 ± 1.5	3.6 ± 2.3	0.37	0.13
Hemoglobin (g/L)	12.0 ± 1.3	11.4 ± 1.3	−0.52	0.017
Magnesium (mmol/L)	0.5 ± 0.1	0.4 ± 0.08	−0.09	<0.001
Calcium (mmol/L)	1.2 ± 0.2	1.1 ± 0.2	−0.10	<0.001

Interleukin6 (IL-6). A linear mixed model was built to analyze the parameters before and after switching to citrate-acidified A concentrates (with treatment as the main effect: citrate = 1, acetate = 0).  < 0.05 was considered significant. Missing values were as follows: in acetate treatment, C-reactive protein/hemoglobin, n = 2; IL-6, n = 3; neutrophils, n = 1; neutrophils/lymphocytes, n = 1; in citrate treatment, C-reactive protein, n = 1; IL-6, n = 3; magnesium/calcium, n = 2.